Uzbek officials said distributors of toxic cough syrup produced by Noida -based Marian Biotech Ltd had been bribed to release the drug on the market.
Uzbek state prosecutors alleged during the trial that a cough syrup distributor paid a $33,000 bribe to avoid mandatory testing, the news agency reported.
A case of 65 children died after consuming cough syrup (Doc 1 Max) produced by an Indian-based company in a Central Asian country.
In December last year, the government of Uzbekistan announced that 20 children died in our country after consuming cough syrup. However, the country’s health ministry raised the death toll to 65. However, the government has not clarified how the deaths of 45 children remained unreported.
India has permanently revoked the manufacturing license of a drug produced by Marion-Biotech Ltd after it was reported that it contained the deadly compound ethylene glycol.
However, it is unclear whether the inspection should include tests in Uzbekistan or whether the manufacturer should conduct tests in India. The Central Asian country has prosecuted 21 people, including an Indian, in connection with the case.
Seven of the 21 accused pleaded guilty to some of the charges against them. These include allegations of tax evasion, sale of substandard or counterfeit drugs, abuse of office, negligence, forgery, and bribery.
A year ago, Gambia imported poisoned paracetamol syrups produced by Maiden Pharmaceuticals Limited of India, and 66 children died of acute kidney infections after consuming the syrup.
According to media reports, most of the children were under the age of 2 and died between June and September 2022.
In February this year, the US Food and Drug Administration warned against using an eye drop made by India’s Global Pharma Healthcare Pvt Ltd. It was ordered not to be used after an outbreak caused adverse events in at least 55 patients, including infections, blindness, and one death.
Many Indian firms have come under scrutiny for the quality of their medicines in recent months. Experts have raised concerns about the manufacturing factors used to make these drugs.

